# A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

> **NCT06561074** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 22 (estimated)

## Conditions studied

- T-cell Acute Lymphoblastic Leukemia
- T-Cell Lymphoblastic Lymphoma

## Interventions

- **DRUG:** Decitabine
- **DRUG:** Venetoclax
- **DRUG:** Calaspargase pegol-mknl

## Key facts

- **NCT ID:** NCT06561074
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-25
- **Primary completion:** 2029-12-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06561074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06561074, "A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06561074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*